Massive study pits semaglutide against dulaglutide to protect hearts in diabetes

NCT ID NCT07619495

Completed Disease control Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 3 times

Summary

This study looks at health records of 120,000 people with type 2 diabetes and overweight to compare two injectable drugs: semaglutide and dulaglutide. Researchers want to see which one better reduces the risk of death, heart attack, or stroke. The goal is to understand how these drugs work in real-world settings, not just in controlled trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: semaglutide and dulaglutide (injectable diabetes medications)
What this could lead to: If successful, this could show which drug is more effective at preventing heart attacks, strokes, or death in people with type 2 diabetes and overweight.
What could go wrong: This is an observational study using existing health records, not a controlled trial, so results may be less reliable. It also does not test a new treatment, just compares two existing drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY OVERWEIGHT TYPE 2 DIABETES MELLITUS

Contacts and locations

Locations

Brigham and Women's Hospital

Boston, Massachusetts, 02120, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.